@johndavis60 - Hi John, Thanks! Just the opposite. Somatic testing identified a SPOP alteration which typically indicates..."increased clinical benefit from AR signaling inhibitors." That's why the decision was made to go with with Orgovyx and Nubeqa from the beginning immediately following diagnosis. The short timeframe to castrate resistance is a complete surprise. We (GUO & I) are hopeful that the ARSI (Nubeqa) is still doing its job as expected, however, the unexpected and rapid increase in PSA would dispute that. Blood was drawn for a Foundation One Liquid CDx test to identify any other pertinent genetic alterations; however, I haven't seen results yet. PSMA PET scan will let us know if things are running wild or reasonably controlled. I'm not expecting very good results. Last visit, doc looked up from reading test results and said, "Wow, you're very weird."

Think I'll go float a Cheerio in my morning single malt now. 🤣🤣🤣